semaglutide pioneer Oral versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial Efficacy, safety and cardiovascular outcomes

+Why researchers find BPC-157 interesting BPC-157 is interesting because it appears to act 'systemically wherever it's needed' rather than at a single receptor it is one of the few peptides whose effects don't track to a clean target/pathway diagram, which is exactly why so much research is still being done on it

Liposomal delivery uses a protective fat layer to help the nutrient survive digestion and improve absorption at the cellular level

Oral semaglutide is daily if you prefer no injections, though less effective for weight loss than injectable

Diabetes Obes Metab 20(3):571581

Wenn die belkeit mehr als 24 Stunden anhlt oder von Erbrechen begleitet wird, sollte die aktuelle Dosis fr eine weitere Woche beibehalten oder auf die vorherige Dosisstufe reduziert werden